Research Analysts’ Recent Ratings Changes for VolitionRx (VNRX)

A number of research firms have changed their ratings and price targets for VolitionRx (NYSE: VNRX):

• 3/20/2025 – VolitionRx is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.
• 3/20/2025 – VolitionRx had its “buy” rating reaffirmed by analysts at D. Boral Capital. They now have a $5.00 price target on the stock.
• 3/12/2025 – VolitionRx is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.
• 3/12/2025 – VolitionRx had its “buy” rating reaffirmed by analysts at D. Boral Capital. They now have a $5.00 price target on the stock.
• 3/4/2025 – VolitionRx is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.
• 3/4/2025 – VolitionRx had its “buy” rating reaffirmed by analysts at D. Boral Capital. They now have a $5.00 price target on the stock.
• 2/24/2025 – VolitionRx is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.
• 2/16/2025 – VolitionRx is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.
• 2/8/2025 – VolitionRx is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.
• 2/6/2025 – VolitionRx had its “buy” rating reaffirmed by analysts at D. Boral Capital. They now have a $5.00 price target on the stock.
• 1/31/2025 – VolitionRx is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.
• 1/29/2025 – VolitionRx had its “buy” rating reaffirmed by analysts at D. Boral Capital. They now have a $5.00 price target on the stock.

VolitionRx Stock Performance

Shares of VolitionRx stock opened at $0.55 on Wednesday. VolitionRx Limited has a 52-week low of $0.43 and a 52-week high of $1.02. The business’s 50 day simple moving average is $0.59 and its 200 day simple moving average is $0.64. The firm has a market cap of $51.23 million, a PE ratio of -1.54 and a beta of 1.09.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. Lagoda Investment Management L.P. lifted its position in VolitionRx by 24.3% during the 4th quarter. Lagoda Investment Management L.P. now owns 7,576,000 shares of the company’s stock worth $4,546,000 after buying an additional 1,481,000 shares in the last quarter. Geode Capital Management LLC raised its holdings in VolitionRx by 15.1% during the third quarter. Geode Capital Management LLC now owns 730,448 shares of the company’s stock worth $439,000 after acquiring an additional 95,900 shares in the last quarter. Northern Trust Corp boosted its position in VolitionRx by 32.0% during the fourth quarter. Northern Trust Corp now owns 117,875 shares of the company’s stock valued at $71,000 after purchasing an additional 28,579 shares during the last quarter. Millennium Management LLC bought a new position in VolitionRx in the fourth quarter valued at approximately $36,000. Finally, Two Sigma Securities LLC acquired a new position in shares of VolitionRx during the 4th quarter worth approximately $29,000. Institutional investors and hedge funds own 8.09% of the company’s stock.

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.